symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
OTLC,0.036,-0.01925,126321,14333724,0,0.01-0.1,0.006,"Oncotelic Therapeutics, Inc.",USD,0000908259,,628341109,Other OTC,PNK,Biotechnology,https://www.oncotelic.com,"Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ÃŸ2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.",Dr. Vuong  Trieu Ph.D.,Healthcare,US,22,650 635 7000,29397 Agoura Road,Agoura Hills,CA,91301,,0,https://financialmodelingprep.com/image-stock/OTLC.png,1993-08-26,False,False,True,False,False
